Loading...
•
Sep 30, 2022
Generation Bio Q3 2022 Earnings Report
Generation Bio's financial results for Q3 2022 were announced, revealing a net loss of $31.3 million and a cash balance of $301.2 million expected to fund operations into 2025.
Key Takeaways
Generation Bio reported a net loss of $31.3 million for Q3 2022. The company's cash, cash equivalents, and marketable securities totaled $301.2 million, expected to fund operations into 2025. Phillip Samayoa, Ph.D. was named chief strategy officer.
Cash, cash equivalents and marketable securities were $301.2 million as of September 30, 2022.
Research and development expenses were $21.2 million for the quarter ended September 30, 2022.
General and administrative expenses were $11.5 million for the quarter ended September 30, 2022.
Net loss was $31.3 million, or $0.53 basic and diluted net loss per share, for the quarter ended September 30, 2022.